BiotechTube

Ofloxacin + Avelox (Moxifloxacin, BAY12-8039)

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pelvic Inflammatory Disease

Conditions

Pelvic Inflammatory Disease

Trial Timeline

Apr 1, 2003 → Oct 1, 2004

NCT ID
NCT00683865

About Ofloxacin + Avelox (Moxifloxacin, BAY12-8039)

Ofloxacin + Avelox (Moxifloxacin, BAY12-8039) is a phase 3 stage product being developed by Bayer for Pelvic Inflammatory Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00683865. Target conditions include Pelvic Inflammatory Disease.

What happened to similar drugs?

3 of 5 similar drugs in Pelvic Inflammatory Disease were approved

Approved (3) Terminated (1) Active (2)
✅Solifenacin + PlaceboAstellas PharmaApproved
🔄AzithromycinPfizerPhase 3
✅Conjugated Estrogens Cream + Placebo CreamPfizerApproved
🔄Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & MetronidazoleBayerPhase 3
✅Sevoflurane + propofol + remifentanilBaxterApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00683865Phase 3Completed

Competing Products

11 competing products in Pelvic Inflammatory Disease

See all competitors
ProductCompanyStageHype Score
Solifenacin + PlaceboAstellas PharmaApproved
35
BGS649 + PlaceboNovartisPhase 2
27
Tanezumab + PlaceboPfizerPhase 2
35
AzithromycinPfizerPhase 3
40
Vaginal estrogen + PlaceboPfizerPre-clinical
18
Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tabletPfizerPhase 2
27
Conjugated Estrogens Cream + Placebo CreamPfizerApproved
43
BAY1834845 + PlaceboBayerPhase 1
26
Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & MetronidazoleBayerPhase 3
37
Dienogest (BAY86-5258, Visanne)BayerPre-clinical
23
Sevoflurane + propofol + remifentanilBaxterApproved
40